Why This Summit Is Unmissable for Academics
Shape the Next Generation of RNA-Targeted Therapeutics.
Connect your research with the biotech and pharma organizations translating RNA biology into therapeutic programs. The next generation of RNA-targeted therapeutics will emerge from closer collaboration between academia and industry.
Join the biotech and pharma teams translating RNA biology into therapeutic programs and discover how your research can influence drug discovery, target validation, structure prediction, and translational development efforts.
Challenges We Help Solve
Translating RNA Biology Into Therapeutic Applications
Understand how industry is transforming fundamental discoveries into drug development opportunities.
Understanding Industry's Most Pressing Bottlenecks
Learn where pharma and biotech organizations need new scientific solutions.
Advancing RNA Structure & Interaction Analysis
Explore the latest technologies used to characterize RNA structures, binding pockets, conformational dynamics, and molecular interactions.
Identifying High-Impact Research Opportunities
Discover where future funding, collaboration, and industry interest are likely to emerge.
Building New Industry Collaborations
Connect with organizations seeking novel technologies, targets, and platform capabilities.
Priority Sessions for Academics
Translating RNA Biology Into Therapeutically Relevant Targets
Workshop A: Identifying Functional RNA Targets at Scale to Prioritize Therapeutically Relevant Discovery Hypothesis
Speakers:
- Dalya Gartzman, Chief Executive Officer & Co-Founder, Renasis Bio
- Dominic Reynolds, Chief Scientific Officer, Remix Therapeutics
- Stefan Schiesser, Director, Medicinal Chemistry, AstraZeneca
Understand how industry evaluates RNA targets, prioritizes biological relevance, and transforms fundamental RNA biology into therapeutic opportunities.
Understanding RNA Structure & Druggability
Conference Day One: Modelling Approaches to Understand RNA Structure, Dynamics & Small Molecule Binding to Guide Target Selection & Improve Small Molecule Design
Speaker:
- Paraskevi Gkeka, Distinguished Scientist, Group Head CADD, Sanofi
Explore how computational modelling, RNA dynamics, and binding-site prediction are driving the next generation of RNA-targeted drug discovery.
Characterizing Functionally Meaningful RNA-Protein Complexes
Conference Day Two: Roundtable Discussion: Characterizing Functionally Meaningful RNA-Protein Complexes to Enable Productive Drug Discovery
Speakers:
- Nikolai Naryshkin, Chief Scientific Officer, Ribonaut Therapeutics
- Aaron Hoskins, University of Wisconsin–Madison
Discover how industry is connecting RNA structure, protein interactions, and functional biology to identify mechanisms most likely to generate therapeutic success.
Benchmark Your Strategy Against Peers
Questions you could ask your peers to benchmark against them:
Which RNA targets are attracting the most industry investment?
What translational evidence matters most to drug developers?
Which discovery technologies have the highest adoption?
Where are the biggest opportunities for academic-industry collaboration?
Which disease areas are creating new opportunities?
What Past Attendees Say
Engaging with fellow innovators allows us to collectively address the field's challenges, explore new frontiers, and build partnerships that will define the next generation of medicines.
The highly engaged audience and the frank exchange of technical challenges made the sessions particularly valuable. It was also inspiring to see how different groups are approaching RNA-targeted small molecules from diverse angles, which made the conversations both enjoyable and thought-provoking.
Explore the Agenda
Hear the latest industry advances in RNA target selection, structure-guided design, selective modulation and translational strategies across the full RNA-targeted small molecule pipeline and during our packed agenda, interactive roundtables, and panel discussions.
Partner With Us
Position yourself alongside other leading solution providers to ensure your brand is at the heart of biopharma deals.
Join Biopharma Experts
Connect with RNA-targeted small molecule leaders across discovery, preclinical and clinical development during our dedicated networking sessions to exchange insights, build collaborations and strengthen decisions from target selection to therapeutic impact.